Progression-free survival was superior with first-line maintenance of palbociclib in HR-positive, HER2-positive metastatic ...

Not only are they the smallest among us, but premature children also face health and life challenges that make them the most ...

Adjuvant olaparib continued to show a strong efficacy benefit in patients with BRCA1/2 mutation–positive, HER2-negative high-risk breast, according to 6-year data from the OlympiA trial.

The survival rate for children with a rare but deadly cancer could one day be improved by adding an existing drug—which is ...

Real-world study compares the efficacy and safety of axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel), ...

Children from low-income households are more likely to experience cancer relapse and face lower survival rates.

Adding pyrotinib to trastuzumab and docetaxel prolonged progression-free survival in patients with HER2-positive metastatic breast cancer.

The Centre is a collaboration between the ICR and The Royal Marsden NHS Foundation Trust driving pioneering research for ...

Smaller businesses backed by the government’s Start Up Loans programme have higher survival rates than other businesses, ...

Pancreatic cancer is often called a 'silent cancer' because its symptoms can be vague or mistaken for other conditions - but ...

The benefit of the PARP inhibitor in patients with germline BRCA pathogenic variants remains evident 10 years after the first ...

Cardiff Oncology's phase 2 trial of onvansertib in mCRC shows promising results, with improved response rates and potential ...